The National Multiple Sclerosis Society and the International Pediatric Multiple Sclerosis Study Group are pleased to invite you to participate in the International Pediatric ECHO MS Program. This program is designed to foster international collaboration and increase expertise in pediatric MS and related demyelinating disease. International Pediatric ECHO MS follows the evidence-based Project ECHO® guided-practice model for reducing healthcare disparities and improving patient outcomes. Since 2003, this hub and spoke model has proven effective in over 180 countries worldwide.

Please join us in 2022 for three 90-minute ECHO sessions and earn up to 4.5 AMA PRA Category 1 Credits. Participants will be invited to present their patients and the hub team will provide expert opinion and recommendations. The hub team will also lead didactic discussions on Pediatric MS, Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD), and Aquaporin-4 Antibody positive (AQP4-Ab) Neuromyelitis Optica Spectrum Disorder (NMOSD).

**2022 Schedule - International Pediatric ECHO MS**

- Monday, January 31, 2022 | 7:00 – 8:30 AM PT
- Monday, June 13, 2022 | 7:00 – 8:30 AM PT
- Monday, September 12, 2022 | 7:00 – 8:30 AM PT

**HUB Team - International Pediatric ECHO MS**

Co-Directors
- Brenda Banwell, MD, FRCPC, FAAN – The Children’s Hospital of Philadelphia
- Cheryl Hemingway, MBChB, PhD – Great Ormond Street Hospital for Children

Hub Team Members
- Thais Arangue, MD, PhD – Sant Joan de Deu, Barcelona Hospital, Spain
- Frederik Barkhof, MD, PhD – Amsterdam University Medical Centers, Netherlands
- Jennifer Graves, MD, PhD – University of California San Diego, USA
- Barbara Kornek, MD – Medical University of Vienna, Austria
- Lekha Pandit, MD, DM, PhD – Nitte University, India

**Additional Information and Registration: [www.nationalmssociety.org/ECHOMS](http://www.nationalmssociety.org/ECHOMS)**

Physicians and trainees treating pediatric patients with multiple sclerosis and related demyelinating disease are welcome to join. The expectation is for participants to commit to attending all three sessions. Physicians will earn up to 4.5 AMA PRA Category 1 Credits.
AMA Designation Statement

Project ECHO® designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

Project ECHO®, in compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, requires that anyone who is in a position to control the content of an educational activity disclose all relevant financial relationships they have had within the last 24 months with an ineligible company.

The following planners / presenters for this educational activity do not have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Darren Ball, M.Ed.
Lekha Pandit, MD, DM, PhD

The following planners / presenters listed below have disclosed that they have a relevant financial relationship with an ineligible company.

<table>
<thead>
<tr>
<th>Name of Planner / Presenter</th>
<th>Nature of Relationship</th>
<th>Name of Ineligible Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brenda Banwell, MD, FRCPC, FAAN</td>
<td>Consultant</td>
<td>Novartis, Roche, UCB, Sanofi</td>
</tr>
<tr>
<td>Cheryl Hemingway, MBChB, PhD</td>
<td>Consultant, Speaker</td>
<td>Novartis, Biogen, VielaBio, Roche, UCB, Novartis, Roche</td>
</tr>
<tr>
<td>Thais Armangue, MD, PhD</td>
<td>Advisor, Speaker</td>
<td>Biogen, Sanofi, Biogen, Novartis</td>
</tr>
<tr>
<td>Frederik Barkhof, MD, PhD</td>
<td>Consultant</td>
<td>Biogen, Roche, Merck, Combinostics, Janssen</td>
</tr>
<tr>
<td>Jennifer Graves, MD, PhD</td>
<td>Advisor, Steering Committee, Speaker</td>
<td>Genentech, Bayer, Novartis, Alexion</td>
</tr>
<tr>
<td>Barbara Kornek, MD</td>
<td>Advisor, Speaker</td>
<td>BMS Celgene, Johnson &amp; Johnson, Merck, Novartis Roche, Biogen, BMS Celgene, Mereck, Novartis, Roche</td>
</tr>
</tbody>
</table>

All of the relevant financial relationships listed for these individuals have been mitigated.